Search Results - Oncology

27 Results

Sort By:

Novel tasquinimod analogs having novel anticancer activity

Project ID: TECH-2025-31 Background Disruption of microtubules has dramatic effects on cell division due to the essential role they play in conjunction with the mitotic spindles during this process. Molecules that disrupt microtubule function are currently in widespread clinical use in cancer treatment. Taxanes, vinca alkaloids, and epothilones are...

PTH1R PROTAC

Project ID: TECH-2025-20 Background Every 16 mins a man will die of Prostate cancer. Bone metastasis is the predominant cause of morbidity and mortality in prostate cancer, with > 80 % of lethal cases exhibiting skeletal involvement. Parathyroid hormone-related protein (PTHrP), secreted by tumor cells, binds and activates PTH1R on osteoblasts and...

Confederated C Prime Agents vs Cancers (PDAC) & Metabolic Disorders

Project ID: D2020-28 Background Based upon the success of a mixture of simvastatin (SIM) + metformin (Met) + digoxin (Dig), dubbed “C3”, for treating pancreatic ductal adenocarcinoma (PDAC) via a pleiotropic mechanism where attenuation of the BIRC5 pathway is a major component, we have pursued novel, single-molecular constructs that combine...

Analogs of peroxisome proliferator activiated receptor (PPAR) agonists, and methods of using the same

Novel PPARδ Agonists for Bone Growth Background Osteoporosis is a silent disease of bones that affects tens of millions of people over the age of 50 with direct medical costs of over $31 billion yearly due to injuries from falls. With the aging population of the US there is a serious need for effective treatments to combat bone...

Advancement in Platinum Based Cancer Therapeutics

Project ID: D2013-02 Novelty: Small drug like molecules that inhibits DNA repair factors for cisplatin (and other platinum based drugs) resistance towards solid tumors, thereby increasing cisplatin cytotoxicity and efficacy. Value proposition: One of the limitations of chemotherapy in ovarian cancer is the innate/acquired drug resistance in cancer...

Survivin Inhibitors for Targeted Cancer Treatment

Project ID: TECH-2024-07 Background Prostate cancer is one of the most common cancers and the second-most lethal cancer among men in the United States. While the response to standard androgen deprivation therapy (ADT) is often dramatic, most prostate cancer patients develop resistance to ADT, leading to castration-resistant prostate cancer (CRPC)....

Smart Exosomes Enable Active Pdac Targeting and Evading Mononuclear Phagocycotic System

Project ID: D2021-13 Background Patients affected by pancreatic ductal adenocarcinoma (PDAC), an aggressive type of cancer, have a 5-year survival rate of 9%, the lowest of any cancer in the US. Therapies for pancreatic cancer are largely hindered by the lack of an effective delivery system. Exosomes are emerging as promising nanocarriers for genes...

Metabolically stable HDAC inhibitors with trifluoromethylpyruvamide as metal-binding group

Project ID: TECH-2023-25 Background Histone Deacetylases (HDACs) have been studied extensively for their role in regulating expression of genes and proteins involved in cancer cell proliferation and migration. The Zinc Binding Group (ZBG) is an essential component of the HDAC inhibitor pharmacophore. It binds to the zinc ion in the enzyme active...

Antiproliferative necroptosis inducers or autophagy inhibitors or a combination thereof

Background Breast cancer is the leading cause of cancer-related deaths in women worldwide, and triple negative breast cancer (TNBC) accounts for approximately 15-20% of these cancers. TNBC tumors do not express three key therapeutically relevant cell-surface receptors: estrogen receptor (ER), progesterone receptor (PR), and overexpression of...

Novel Ferroptosis Inducers To Treat Cancer

Project ID: D2022-15 Background ferroptosis is a non-apoptotic cell death mechanism impelled by unrestrained accumulation of iron-dependent cellular reactive oxygen (ROS) species leading to membrane lipid peroxidation resulting from intra-cellular antioxidant depletion. Clinical application of ferroptosis agents/drugs has been elusive due to off-target...

1 2 3